உலகளாவிய ஆரோக்கியம் இல் நோவர்த்திச் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from உலகளாவிய ஆரோக்கியம் இல் நோவர்த்திச். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In உலகளாவிய ஆரோக்கியம் இல் நோவர்த்திச் Today - Breaking & Trending Today

Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts

Can Novartis really make its medicines available to everyone?


Can Novartis really make its medicines available to everyone?
Novartis launched a new strategy in sub-Saharan Africa in 2019. Sales people will no longer be incentivised by sales targets but rather by patients reached. Reuters / Baz Ratner
Swiss pharma firm Novartis has said it wants everyone in the world to be able to access its products, even multi-million-dollar gene therapies. Can its experiment work?
This content was published on February 10, 2021 - 09:00
February 10, 2021 - 09:00
Jessica Davis Plüss
Jessica covers the good, the bad, and the ugly when it comes to big global companies and their impact in Switzerland and abroad. She’s always looking for a Swiss connection with her native San Francisco and will happily discuss why her hometown has produced some of the greatest innovations but can’t seem to solve its housing crisis. ....

United States , South Africa , Jenna Denyes , Lutz Hegemann , Veronika Wirtz , Yannis Natsis , Jayasree Iyer , Vicki Pinkney Atkinson , Global Health At Novartis , Boston University , European Public Health Alliance , World Health Organisation Executive Board , Access To Medicine Foundation Indexexternal , Group Head Of Corporate Affairs , Access To Medicine Foundation , Medicine Foundation Indexexternal , Saharan Africa , Group Head , Corporate Affairs , Global Health , Medicine Foundation , Medicine Index , Pinkney Atkinson , ஒன்றுபட்டது மாநிலங்களில் , லூட்ஸ் ெகேமன்ன் , வெரோனிகா வர்ட்ஸ் ,

Novartis Renews WHO Medicine Donation Pledge With Aim of End


Visit Novartis Global Health on Twitter and Linkedin.
Friday, January 29, 2021 - 1:15am
CONTENT: Press Release
BASEL, SWITZERLAND,  January 29, 2021 /3BL Media/ A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 – will see Novartis continue to donate multidrug therapy (MDT) medicines to treat leprosy up to the end of 2025.
Widespread use of MDT has led to a 95% reduction in leprosy prevalence world-wide since its introduction the 1980s, though more than 200,000 cases are still seen every year.
1 Despite the huge impact of MDT, governments, donors, civil society and the private sector will need to collaborate on deploying additional tools if the world is to get to zero leprosy. ....

United States , Isabella Zinck , Samir Shah , Lutz Hegemann , Thomas Hungerbuehler , Sloan Simpson , Ren Minghui , Novartis Global Health Corporate Responsibility , Health Coverage Communicable , Global Health At Novartis , Lancet Global Health , World Health Organization , Novartis Global Health Corporate Responsibility Unit , Global Partnership For Zero Leprosy , Exchange Commission , Novartis Foundation , Chief Operating Officer , Global Health , Global Partnership , Zero Leprosy , Assistant Director General , Universal Health Coverage , Non Communicable Diseases , Novartis Global Health , Corporate Responsibility Unit , Corporate Responsibility ,

GSK and Novartis Announce Funding for Scientific Research in Africa


–Combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years
GSK and Novartis yesterday announced the launch of a collaboration to support high-quality scientific research investigating the link between genetic diversity across different regions in Africa and its potential impact on response to drug therapeutics.
The Project Africa Genomic Research Approach for Diversity and Optimising Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8m (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis.1
Pauline Williams, Senior Vice President Global Health Pharma at GSK said: “At GSK, human genetics is a core pillar of our R&D strategy. Genetic diversity is greater in Africa than in any other continental population resulting in some African patients having varying response to treatments. We are excited ....

Lutz Hegemann , Pauline Williams , Glenda Gray , Global Health Pharma , Novartis Institutes For Biomedical Research On African , Steering Committee , Global Health At Novartis , Africa Medical Research Council , African Medical Research Council , Africa Genomic Research Approach For Diversity , Project Africa Genomic Research Approach , Optimising Therapeutics , Senior Vice President Global Health Pharma , Project Africa , Chief Operating Officer , Global Health , South African Medical Research Council , Joint Steering Committee , South Africa Medical Research Council , Open Lab , Sub Saharan African , Novartis Institutes , Biomedical Research , லூட்ஸ் ெகேமன்ன் , பாலீந் வில்லியம்ஸ் , க்லெஂட சாம்பல் ,

Novartis and GSK announce collaboration to support scientifi


ng
Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis (TB).
1
Lutz Hegemann, M.D., Chief Operating Officer for Global Health at Novartis said: “Novartis has a long-standing commitment to improving and extending the lives of patients around the world.  Our efforts include seeking innovative ways to improve the standard of care where possible. This is why we are excited by this important collaboration on scientific research on genetic diversity in Africa. It has the potential to improve the efficacy and tolerability of current and future medicines, starting with two of the most deadly diseases, malaria and tuberculosis. In alignment with our ongoing efforts to strengthen scientific capabilities in lower-resource settings, this project also provides op ....

United States , Isabella Zinck , Eric Althoff , Thomas Hungerbuehler , Kara Cournoyer , Glenda Gray , Samir Shah , Lutz Hegemann , Sloan Simpson , Katerina Kontzalis , Antonio Ligi , Pauline Williams , Novartis Global Health Corporate Responsibility , Global Health Pharma , Novartis Institutes For Biomedical Research , Novartis Institutes For Biomedical Research On African , Steering Committee , Global Health At Novartis , Global Health Cr Communications , Novartis Us External Communications , Novartis External Communications , Exchange Commission , Africa Medical Research Council , African Medical Research Council , Africa Genomic Research Approach For Diversity , Project Africa Genomic Research Approach ,